Ibrolipim
Alternative Names: NO 1886; OPF 009Latest Information Update: 12 Feb 2008
At a glance
- Originator Otsuka Pharmaceutical
- Developer TAP Pharmaceutical Products
- Class Antihyperglycaemics; Antihyperlipidaemics; Obesity therapies; Small molecules
- Mechanism of Action Lipoprotein lipase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications; Hypertriglyceridaemia; Low HDL cholesterol; Nephrotic syndrome; Obesity
Most Recent Events
- 08 Mar 2004 No development reported - Phase-II for Hypertriglyceridaemia in Japan (unspecified route)
- 08 Mar 2004 No development reported - Phase-II for Low HDL cholesterol in Japan (unspecified route)
- 08 Mar 2004 No development reported - Phase-II for Obesity in Japan (unspecified route)